File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

TitleSerum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
Authors
Issue Date1997
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEI
Citation
Clinical And Experimental Immunology, 1997, v. 107 n. 1, p. 89-95 How to Cite?
AbstractThere are two major forms of the Fas molecule, membranous Fas and soluble Fas (sFas). To clarify the clinical significance of sFas in autoimmune diseases, we designed a sandwich ELISA to determine serum concentrations of sFas and its molecular structure, and we then analysed the correlation between levels of sFas and laboratory findings in patients with SLE and other autoimmune diseases. The levels of serum sFas were significantly higher in SLE patients than in subjects with other autoimmune diseases and in healthy donors, and the frequency of a positive serum sFas was much greater in SLE patients with high SLE disease activity index scores than in those with low scores. In addition, sFas-positive SLE patients showed a significant difference in various laboratory parameters from sFas-negative SLE patients. Serial measurements of serum sFas levels in SLE patients with active disease revealed that the elevated level of sFas dramatically decreased with improvement in clinical and laboratory findings, following corticosteroid therapy. We propose that the serum level of sFas can serve as an appropriate marker for evaluating SLE disease activity. Serum sFas is heterogeneous with respect to molecular structure, thus several mechanisms are involved in the generation of sFas.
Persistent Identifierhttp://hdl.handle.net/10722/179461
ISSN
2015 Impact Factor: 3.148
2015 SCImago Journal Rankings: 1.369
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorJodo, Sen_US
dc.contributor.authorKobayashi, Sen_US
dc.contributor.authorKayagaki, Nen_US
dc.contributor.authorOgura, Nen_US
dc.contributor.authorFeng, Yen_US
dc.contributor.authorAmasaki, Yen_US
dc.contributor.authorFujisaku, Aen_US
dc.contributor.authorAzuma, Men_US
dc.contributor.authorYagita, Hen_US
dc.contributor.authorOkumura, Ken_US
dc.contributor.authorKoike, Ten_US
dc.date.accessioned2012-12-19T09:56:47Z-
dc.date.available2012-12-19T09:56:47Z-
dc.date.issued1997en_US
dc.identifier.citationClinical And Experimental Immunology, 1997, v. 107 n. 1, p. 89-95en_US
dc.identifier.issn0009-9104en_US
dc.identifier.urihttp://hdl.handle.net/10722/179461-
dc.description.abstractThere are two major forms of the Fas molecule, membranous Fas and soluble Fas (sFas). To clarify the clinical significance of sFas in autoimmune diseases, we designed a sandwich ELISA to determine serum concentrations of sFas and its molecular structure, and we then analysed the correlation between levels of sFas and laboratory findings in patients with SLE and other autoimmune diseases. The levels of serum sFas were significantly higher in SLE patients than in subjects with other autoimmune diseases and in healthy donors, and the frequency of a positive serum sFas was much greater in SLE patients with high SLE disease activity index scores than in those with low scores. In addition, sFas-positive SLE patients showed a significant difference in various laboratory parameters from sFas-negative SLE patients. Serial measurements of serum sFas levels in SLE patients with active disease revealed that the elevated level of sFas dramatically decreased with improvement in clinical and laboratory findings, following corticosteroid therapy. We propose that the serum level of sFas can serve as an appropriate marker for evaluating SLE disease activity. Serum sFas is heterogeneous with respect to molecular structure, thus several mechanisms are involved in the generation of sFas.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEIen_US
dc.relation.ispartofClinical and Experimental Immunologyen_US
dc.subject.meshAntigens, Cd95 - Blood - Immunologyen_US
dc.subject.meshAutoimmune Diseases - Immunologyen_US
dc.subject.meshBiological Markers - Analysisen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLupus Erythematosus, Systemic - Immunology - Physiopathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMolecular Structureen_US
dc.titleSerum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseasesen_US
dc.typeArticleen_US
dc.identifier.emailFeng, Y: yfeng@hku.hken_US
dc.identifier.authorityFeng, Y=rp00466en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2249.1997.d01-901.x-
dc.identifier.pmid9010262-
dc.identifier.scopuseid_2-s2.0-8044251511en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8044251511&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume107en_US
dc.identifier.issue1en_US
dc.identifier.spage89en_US
dc.identifier.epage95en_US
dc.identifier.isiWOS:A1997WC59200015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridJodo, S=6701772137en_US
dc.identifier.scopusauthoridKobayashi, S=8083633200en_US
dc.identifier.scopusauthoridKayagaki, N=7004234495en_US
dc.identifier.scopusauthoridOgura, N=36886960200en_US
dc.identifier.scopusauthoridFeng, Y=24467969600en_US
dc.identifier.scopusauthoridAmasaki, Y=6701731311en_US
dc.identifier.scopusauthoridFujisaku, A=7004147273en_US
dc.identifier.scopusauthoridAzuma, M=35372842100en_US
dc.identifier.scopusauthoridYagita, H=35077861000en_US
dc.identifier.scopusauthoridOkumura, K=7402772516en_US
dc.identifier.scopusauthoridKoike, T=7401795755en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats